The latest version of the US health bill includes a provision about generic biotech drugs. The version passed by the House Energy and Commerce Committee gives biotech drugs 12-year exclusivity period, reports the Wall Street Journal Health Blog. The chair of the committee, Henry Waxman, earlier this year called for a five-year period of exclusivity.